The Rockefeller University

University System of Maryland

USA As Represented by Secretary of the Navy

University of Georgia Research Foundation, Inc.

Government of the United States of America, As Represented by the Secretary of Commerce

Daniel Craig Nelson

Vincent A Fischetti

Raymond Schuch

Pauline Yoong

James Travis

Jan Stanislaw Potempa

Zvi Kelman

Irina V Etobayeva

Xiaoran Shang

Jutta M Loeffler

The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including an isolated polypeptide comprising an enzymatically active domain (EAD) of abacteriophage endolysin.

Endolysins active againstbacteria, pharmaceutical compositions, and methods relating thereto

A di-enzymatic chimeric endolysin includes a primary enzymatic active domain including a primary protein sequence and that cleaves a glycosidic, peptide, or amide bond; a secondary enzymatic active domain disposed at a C-terminus end of the di-enzymatic chimeric endolysin and including a secondary protein sequence that, in combination with the primary enzymatic active domain, synergistically cleaves glycosidic, peptide, or amide bonds in a peptidoglycan; a cell wall binding domain including a recognition sequence that is sequentially interposed between the primary protein sequence and the secondary protein sequence and that binds to a cell wall; and a tertiary structure such that the primary enzymatic active domain faces and opposes the secondary enzymatic active domain in the di-enzymatic chimeric endolysin for synergistic cleavage of the peptidoglycan.

Di-enzymatic chimeric endolysin

The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including isolated endolysin polypeptides from bacteriophage GRCS.

[object Object]

The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment ofandbacteria and spores, and related conditions. The disclosure further relates to methods and compositions for the identification of a phage associated lytic enzyme to rapidly and specifically detect and killand other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to,are also provided.

The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment ofandbacteria and spores, and related conditions. The disclosure further relates to compositions comprising various phage associated lytic enzyme that rapidly and specifically detect and killand other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure toare also provided.

The full-length nucleic acid sequence of the Cbacteriophage is disclosed in the present application. The specific regions of the Cgenome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical compositions for treating or preventing streptococcal infections in mammals, for compositions for decontamination of inanimate surfaces and for diagnosis of streptococcal infections.

Nucleic acids and polypeptides of C1 bacteriophage and uses thereof

The present disclosure relates to bacteriophage lysins useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, bacteriophage lysins were isolated and shown to effectively kill various bacteria, including bothand(including vancomycin resistant strains), as well as other human pathogens.

The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment ofbacteria and spores, and related conditions. The disclosure further relates to methods and compositions for the identification of a phage associated lytic enzyme to rapidly killand other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to,are also provided.

An isolated oral bacterial polypeptide having amidolytic activity for cleavage of denatured polypeptides and nondenatured serpin polypeptides and particularly a human &agr; -proteinase inhibitor polypeptide is provided. The mature polypeptide of the invention has a molecular weight of about 70 kD to about 80 kD. Also provided is an isolated nucleic acid sequence encoding the oral bacterial polypeptide of the invention, methods for identifying inhibitors of the polypeptide and compositions such as immunogenic compositions and inhibitor compositions.

Polypeptide having amidolytic activity for a serpin

The invention relates to the identification of C bacteriophage genes that express protein involved in the lysis of bacterial cells during the phage life cycle, lysin and holin. The invention further relates to methods for lysing certain bacteria using lysin, which are useful for example in the treatment of an oral cavity bacterial infection.

Growing community of inventors

Rockville, MD, United States of America

Daniel Craig Nelson